Daily Broadcaster

Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years in the Domain

 Breaking News
  • No posts were found

Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years in the Domain

May 14
00:35 2021
Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years in the Domain

Chemotherapy Induced Peripheral Neuropathy Pipeline
The Chemotherapy Induced Peripheral Neuropathy Pipeline Insight report from DelveInsight offers a detailed overview of the pipeline therapies in various clinical and preclinical stages of growth, their introduction, and how the Chemotherapy Induced Peripheral Neuropathy market is expected to change as a result.

The Chemotherapy Induced Peripheral Neuropathy Pipeline Insight report from DelveInsight offers a detailed overview of the pipeline therapies in various clinical and preclinical stages of growth, their introduction, and how the Chemotherapy Induced Peripheral Neuropathy market is expected to change as a result.

The Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis report gives you a complete picture of the Chemotherapy Induced Peripheral Neuropathy therapeutic landscape, including development stage, product type, route of administration, molecule type, and MOA.

The report addresses a wide range of topics, including market opportunities, challenges, future alliances, strong competitors, and growth strategies.

Some of the Key Highlights from the Chemotherapy Induced Peripheral Neuropathy Market Report

  • There are more than 30+ Chemotherapy Induced Peripheral Neuropathy pipeline therapies in different stages of development, and their expected adoption in the Chemotherapy Induced Peripheral Neuropathy market will significantly increase market revenue.

  • Out of the emerging therapies, Tetrodotoxin and PledOx are in Phase III of clinical development, whereas MP-101 and Ibudilast are in Phase II development phase for Chemotherapy Induced Peripheral Neuropathy.

  • Chemotherapy Induced Peripheral Neuropathy pipeline therapies in the early stage of development include Ricolinostat and APX 3330 in Phase I of clinical trials.

  • Some Chemotherapy Induced Peripheral Neuropathy pipeline therapy which is still in the pre-clinical stage of development include AM 1710.

For more information request sample @ Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis

Chemotherapy Induced Peripheral Neuropathy: Disease Overview

Taxanes, platinum-based drugs, vinca alkaloids, thalidomide, bortezomib, and interferon all cause Chemotherapy-Induced Peripheral Neuropathy (CIPN), which is a normal, dose-dependent side effect of many commonly prescribed chemotherapy and biotherapy drugs. CIPN causes a wide range of symptoms, including physical and emotional discomfort from neuropathic pain, as well as degeneration.

Chemotherapy Induced Peripheral Neuropathy: Symptoms

Exaggerated sensation (neuropathic pain), loss of sensation (numbness, muscle weakness, loss of balance), or both are symptoms of CIPN. Symptoms are normally bilateral and develop in a distal to proximal pattern, starting at the tips of the fingers and toes and progressing to the upper and/or lower extremities.

Chemotherapy Induced Peripheral Neuropathy: Treatment

However, there are no licenced medications to prevent or treat CIPN at this time. Some chemotherapy medications have a higher risk of causing neuropathy. Platinum medications like oxaliplatin, taxanes like docetaxel, vinca alkaloids like vincristine, and myeloma therapies like bortezomib are among them. Neuropathy can also be caused by other chemotherapy medications.

Learn more about CIPN @ CIPN Market Trends

Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis: Drug Profile

Pledox (Calmangafodipir): Egetis Therapeutics

PledOx (also known as calmangafodipir, SP-04) is a first-in-class drug candidate being developed by Pledpharma for the prevention of nerve damage caused by chemotherapy in colorectal cancer patients. Calmangafodipir is currently in Phase III clinical trials for the prevention of chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN) caused by the drug Oxaliplatin in patients with cancer.

Chemotherapy Induced Peripheral Neuropathy Pipeline Therapies and Major Companies

  • Tetrodotoxin: WEX Pharmaceuticals

  • PledOx: Egetis Therapeutics

  • MP-101: Metys Pharmaceuticals AG

  • Ibudilast: MediciNova

  • Ricolinostat: Regenacy pharmaceuticals

  • APX 3330: Apexian Pharmaceuticals

  • AM 1710: MakScientific

Chemotherapy Induced Peripheral Neuropathy Therapeutics Assessment

  • By Product Type

    • Monotherapy

    • Combination Therapy

  • By Stage

    • Discovery

    • Pre-Clinical

    • Phase I

    • Phase II

    • Phase III

    • Pre-registration

  • By Route of Administration

    • Inhalation

    • Intravenous

    • Oral

    • Subcutaneous

  • By Molecule Type

    • Small Molecule

    • Stem Cell Therapy

    • Gene Therapy

  • Targets

    • Immune System

    • Multiple Kinase

  • By Mechanism of Action

    • Protease Inhibitors

    • Immunomodulatory

Scope of the Report

Coverage: Global

Key CIPN Players: WEX Pharmaceuticals, Egetis Therapeutics, Metys Pharmaceuticals AG, MediciNova, Regenacy pharmaceuticals, Apexian Pharmaceuticals, MakScientific, among others.

Key CIPN Pipeline Therapies: Tetrodotoxin, PledOx, MP-101, Ibudilast, Ricolinostat, APX 3330, AM 1710, others.

Table of Contents

1.

Introduction

2.

Executive Summary

3.

Chemotherapy Induced Peripheral Neuropathy: Overview

4.

Chemotherapy Induced Peripheral Neuropathy- Analytical Perspective In-depth Commercial Assessment

5.

Chemotherapy Induced Peripheral Neuropathy Pipeline Therapeutics

6.

CIPN Late Stage Products (Phase III)

7.

CIPN Mid Stage Products (Phase II)

8.

CIPN Early Stage Products (Phase I)

9.

CIPN Preclinical Stage Products

10.

CIPN Therapeutic Assessment

11.

CIPN Inactive Products

12.

Company-University Collaborations (Licensing/Partnering) Analysis

13.

Chemotherapy Induced Peripheral Neuropathy Key Companies

14.

Chemotherapy Induced Peripheral Neuropathy Key Products

15.

Chemotherapy Induced Peripheral Neuropathy- Unmet Needs

16.

Chemotherapy Induced Peripheral Neuropathy- Market Drivers and Barriers

17.

Chemotherapy Induced Peripheral Neuropathy- Future Perspectives and Conclusion

18.

CIPN Analyst Views

19.

Appendix

20.

About DelveInsight

Get in touch with our Business executive @ Chemotherapy Induced Peripheral Neuropathy Pipeline Insights to know more

Key Questions Answered in the Chemotherapy Induced Peripheral Neuropathy Report

  • What treatment options are available for Chemotherapy-Induced Peripheral Neuropathy?

  • How many companies are working on treatments for Chemotherapy-Induced Peripheral Neuropathy (CIPN)?

  • What are the main therapies that these companies in the industry have developed?

  • How many therapies are being developed for the treatment of Chemotherapy Induced Peripheral Neuropathy by each company?

  • How many Chemotherapy Induced Peripheral Neuropathy emerging therapies are in progress for the treatment of Chemotherapy Induced Peripheral Neuropathy at the early, mid, and late stages?

  • How many therapies are offered as monotherapies and in conjunction with other therapies out of the total pipeline products?

  • What are the main industry-industry and industry-academia partnerships, mergers and acquisitions, and major licencing activities that will have an effect on Chemotherapy Induced Peripheral Neuropathy?

Related Reports

Chemotherapy Induced Nausea and Vomiting Market

Get comprehensive historical and forecast analysis of Chemotherapy Induced Nausea and Vomiting Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Camurus, LP Pharmaceuticals, Skye Bioscience, TALLC Corporation, Starton Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/